Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Bioorganic & Medicinal Chemistry
|
September 28, 2017
Therapeutic peptides for CNS indications: Progress and challenges
Bruce H Morimoto
Handbook of Experimental Pharmacology
|
June 21, 2015
Safety Pharmacology in Drug Discovery and Development
Bruce H Morimoto, Erin Castelloe, Anthony W Fox
Journal of Pharmacological and Toxicological Methods
|
June 8, 2019
Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse events
Sabina Paglialunga, Bruce H Morimoto, Matthew Clark, et al.
Expert Opinion on Investigational Drugs
|
August 10, 2007
Looking for novel ways to treat the hallmarks of Alzheimer's disease
Alistair J Stewart, Anthony Fox, Bruce H Morimoto, et al.
Drug, Healthcare and Patient Safety
|
May 2, 2018
Evaluating cardiac risk: exposure response analysis in early clinical drug development
Julie Grenier, Sabina Paglialunga, Bruce H Morimoto, et al.
Therapeutic Delivery
|
July 28, 2012
Drug development of intranasally delivered peptides
Catherine Campbell, Bruce H Morimoto, Daniela Nenciu, et al.
Clinical Pharmacology in Drug Development
|
February 15, 2018
Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes Subjects
Sabina Paglialunga, Bruce H Morimoto, Amparo de la Peña, et al.
Expert Review of Clinical Pharmacology
|
August 27, 2013
Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases
Bruce H Morimoto, Anthony W Fox, Alistair J Stewart, et al.
Expert Review of Clinical Pharmacology
|
December 22, 2016
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines
Sabina Paglialunga, Elliot Offman, Nita Ichhpurani, et al.
Dementia and Geriatric Cognitive Disorders
|
April 19, 2013
A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment
Bruce H Morimoto, Don Schmechel, Joe Hirman, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Bioorganic & Medicinal Chemistry
|
September 28, 2017
Therapeutic peptides for CNS indications: Progress and challenges
Bruce H Morimoto
Handbook of Experimental Pharmacology
|
June 21, 2015
Safety Pharmacology in Drug Discovery and Development
Bruce H Morimoto, Erin Castelloe, Anthony W Fox
Journal of Pharmacological and Toxicological Methods
|
June 8, 2019
Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse events
Sabina Paglialunga, Bruce H Morimoto, Matthew Clark, et al.
Expert Opinion on Investigational Drugs
|
August 10, 2007
Looking for novel ways to treat the hallmarks of Alzheimer's disease
Alistair J Stewart, Anthony Fox, Bruce H Morimoto, et al.
Drug, Healthcare and Patient Safety
|
May 2, 2018
Evaluating cardiac risk: exposure response analysis in early clinical drug development
Julie Grenier, Sabina Paglialunga, Bruce H Morimoto, et al.
Therapeutic Delivery
|
July 28, 2012
Drug development of intranasally delivered peptides
Catherine Campbell, Bruce H Morimoto, Daniela Nenciu, et al.
Clinical Pharmacology in Drug Development
|
February 15, 2018
Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes Subjects
Sabina Paglialunga, Bruce H Morimoto, Amparo de la Peña, et al.
Expert Review of Clinical Pharmacology
|
August 27, 2013
Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases
Bruce H Morimoto, Anthony W Fox, Alistair J Stewart, et al.
Expert Review of Clinical Pharmacology
|
December 22, 2016
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines
Sabina Paglialunga, Elliot Offman, Nita Ichhpurani, et al.
Dementia and Geriatric Cognitive Disorders
|
April 19, 2013
A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment
Bruce H Morimoto, Don Schmechel, Joe Hirman, et al.
Page
of 2